feed,title,long_url,short_url
Benzinga,Xunlei Clocks 11% Sequential Revenue Growth In Q1,https://benzinga.com/news/earnings/22/05/27249183/xunlei-clocks-11-revenue-growth-in-q1-backed-by-cloud-computing-live-streaming-subscription,https://bit.ly/3MpdtNI
Benzinga,Nurix Therapeutics Doses First Patient in Phase 1a/1b Study of NX-5948 For B-cell malignancies,https://benzinga.com/general/biotech/22/05/27250542/nurix-therapeutics-doses-first-patient-in-phase-1a1b-study-of-nx-5948-for-b-cell-malignancies,https://bit.ly/39tJTbf
